Considering the challenges associated with diagnosing PCOS, and in particular the assessment of PCOM, the 2023 International Evidence-based Guidelines for the Assessment and Management of PCOS now recommends measuring serum levels of anti-Müllerian hormone (AMH) as an alternative to TVUS for defining PCOM [23]. This evidence concerns the gene AMH and polycystic ovary syndrome.